KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Net Margin for 7 consecutive years, with 20137.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 2013953.0% year-over-year to 20137.06%, compared with a TTM value of 140.17% through Dec 2025, up 13772.0%, and an annual FY2025 reading of 6632.84%, down 663529.0% over the prior year.
  • Net Margin was 20137.06% for Q4 2025 at Aurinia Pharmaceuticals, down from 42.82% in the prior quarter.
  • Across five years, Net Margin topped out at 42.82% in Q3 2025 and bottomed at 20137.06% in Q4 2025.
  • Average Net Margin over 5 years is 1366.27%, with a median of 43.65% recorded in 2023.
  • The sharpest move saw Net Margin skyrocketed 14498495bps in 2021, then crashed -2013953bps in 2025.
  • Year by year, Net Margin stood at 142.38% in 2021, then soared by 36bps to 91.5% in 2022, then soared by 35bps to 59.6% in 2023, then surged by 104bps to 2.47% in 2024, then plummeted by -816312bps to 20137.06% in 2025.
  • Business Quant data shows Net Margin for AUPH at 20137.06% in Q4 2025, 42.82% in Q3 2025, and 30.79% in Q2 2025.